Skip to main content
Samrat Pharmachem Ltd. logo

Samrat Pharmachem Ltd. — Investor Relations & Filings

Ticker · 530125 ISIN · INE103E01016 LEI · 335800KBT2LES3G9R346 BSE.NS Manufacturing
Open in API
Filings indexed 3 across all filing types
Latest filing 2026-05-30 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 530125

About Samrat Pharmachem Ltd.

https://www.samratpharmachem.com

Samrat Pharmachem Ltd. is a manufacturer and exporter specializing in Iodine and Bromine derivatives. The company produces a comprehensive range of products, including Potassium Iodide, Sodium Iodide, Potassium Iodate, Calcium Iodate, Methyl Iodide, and Periodic Acid. These derivatives are utilized in various applications such as pharmaceutical synthesis, food and salt iodization, animal nutrition, and specialty chemical production. The company emphasizes high-purity standards and technical consistency across its product line to meet the requirements of global markets. Its operations focus on the large-scale synthesis of inorganic and organic iodine compounds, providing essential raw materials for the healthcare, agricultural, and industrial sectors.

Recent filings

Filing Released Lang Actions
The Board considered and adopted the financial results for the quarter and year ended March 31, 2026
Interim / Quarterly Report Classification · 90% confidence The document is a BSE submission titled “Outcome of the Board Meeting,” dated May 30, 2026, which encloses the “Audited Financial Results” for the quarter and year ended March 31, 2026. It includes complete financial statements (P&L, assets & liabilities, cash flows) and the auditor’s report. This is more than a high-level earnings release and is not a full annual report (10-K). Therefore, it fits our definition of an Interim / Quarterly Report (comprehensive financial report for a period shorter than a full year). FY 2026
2026-05-30 English
Audited Financial Results for the quarter and year ended 31st March, 2026
Interim / Quarterly Report Classification · 85% confidence The document is a formal filing to the stock exchange under SEBI Regulation 33, titled “Outcome of the Board Meeting,” and encloses the audited financial results (standalone) for the quarter and year ended March 31, 2026, together with the statement of assets & liabilities, cash flows, auditors’ report, and notes. It is not merely a short announcement or link to a report (so not RPA/RNS), nor is it a full narrative annual report (10-K) or just a press‐style earnings summary (ER). Instead, it provides comprehensive financial statements and audit conclusions for a period shorter than a full fiscal year (the quarter) alongside year-end results, matching the criteria for an Interim/Quarterly Report. FY 2026
2026-05-30 English
Annual Secretarial Compliance for the year ended 31-March-2026
Regulatory Filings Classification · 91% confidence The document is an Annual Secretarial Compliance Report prepared by a Practising Company Secretary under SEBI LODR Regulation 24A, which is an officer’s attestation/certification regarding regulatory compliance. It does not contain financial statements or management discussion and is not announcing or publishing another report. Per the certification rule, such compliance certificates are classified as general regulatory filings. Hence, the appropriate category is Regulatory Filings (RNS).
2026-05-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.